Unknown

Dataset Information

0

Expression optimization of a cell membrane-penetrating human papillomavirus type 16 therapeutic vaccine candidate in Nicotiana benthamiana.


ABSTRACT: High-risk human papillomaviruses (hr-HPVs) cause cervical cancer, the fourth most common cancer in women worldwide. A HPV-16 candidate therapeutic vaccine, LALF32-51-E7, was developed by fusing a modified E7 protein to a bacterial cell-penetrating peptide (LALF): this elicited both tumour protection and regression in pre-clinical immunization studies. In the current study, we investigated the potential for producing LALF32-51-E7 in a plant expression system by evaluating the effect of subcellular localization and usage of different expression vectors and gene silencing suppressors. The highest expression levels of LALF32-51-E7 were obtained by using a self-replicating plant expression vector and chloroplast targeting, which increased its accumulation by 27-fold compared to cytoplasmic localization. The production and extraction of LALF32-51-E7 was scaled-up and purification optimized by affinity chromatography. If further developed, this platform could potentially allow for the production of a more affordable therapeutic vaccine for HPV-16. This would be extremely relevant in the context of developing countries, where cervical cancer and other HPV-related malignancies are most prevalent, and where the population have limited or no access to preventative vaccines due to their typical high costs.

SUBMITTER: Yanez RJR 

PROVIDER: S-EPMC5553638 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5210503 | BioStudies
2015-01-01 | S-EPMC4705232 | BioStudies
2015-01-01 | S-EPMC4577214 | BioStudies
2015-01-01 | S-EPMC4676430 | BioStudies
2020-01-01 | S-EPMC7137215 | BioStudies
2019-01-01 | S-EPMC6664019 | BioStudies
2018-01-01 | S-EPMC5805635 | BioStudies
2012-01-01 | S-EPMC3571619 | BioStudies
2020-01-01 | S-EPMC7313545 | BioStudies
2017-01-01 | S-EPMC5336664 | BioStudies